DXCM•benzinga•
Dexcom Sees FY25 Adj. EBITDA Margin 30%; Revenue Growth 14%; FY25 Revenue $4.60B.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 13, 2025 by benzinga